Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome

Journal of Obstetrics and Gynaecology

Volumn 33, Issue 2, 2013, Pages 165-170

  Mohiyiddeen, L ^a   Watson, A J ^a   Apostolopoulos, N V ^a   Berry, R ^a   Alexandraki, K I ^a   Jude, E B ^a  

^a TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

C reactive protein; Endothelial dysfunction; Insulin resistance; Metformin; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

C REACTIVE PROTEIN; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ADULT; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVARY; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84874435280     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2012.745839     Document Type: Article

References (39)

1. Alexandraki K, Protogerou AD, Papaioannou TG, Piperi C, Mastorakos G, Lekakis J et al. 2006. Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens) 5: 126-136
2. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D et al . 1995 . Close relation of endothelial function in the human coronary and peripheral circulations . Journal of the American College of Cardiology 26: 1235-1241
3. Belli SH, Graffi gna MN, Oneto A, Otero P, Schurman L, Levalle OA . 2004 . effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome . Fertility and Sterility 81 : 624-629
4. Bergman RN, Prager R, Volund A, Olefsky JM . 1987. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp . Journal of Clinical Investigation 79 : 790-800
5. Clark AF, Marcellus S, deLory B, Bird CE . 1975. Plasma testosterone free index: A better indicator of plasma androgen activity? Fertility and Sterility 26 : 1001-1005
6. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A . 1998a . Therapeutic eff ects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome . European Journal of Endocrinology 138 : 269-274
7. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ . 1998b . The effect of a pure antiandrogen receptor blocker, fl utamide, on the lipid profi le in the polycystic ovary syndrome . Journal of Clinical Endocrinology and Metabolism 83: 2699-2705
8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG et al . 1999 . A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profi le. Journal of Clinical Endocrinology and Metabolism 84: 4006-4011
9. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G . 2004 . Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome . Journal of Clinical Endocrinology and Metabolism 89: 1273-1276
10. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I et al. 2006. Indices of low-grade chronic infl ammation in polycystic ovary syndrome and the benefi cial effect of metformin Human Reproduction 21: 1426-1431
11. Diamanti-Kandarakis E, Panidis D . 2007. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS . Clinical Endocrinology 67 : 735-742
12. Dunaif A . 1997. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis . Endocrine Reviews 18 : 774-800
13. Ehrmann DA . 2005. Polycystic ovary syndrome. New England Journal of Medicine 352: 1223-1236
14. Espey LL . 1980. Ovulation as an infl ammatory reaction-a hypothesis . Biology of Reproduction 22: 73-106
15. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW . 2003. effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome . Fertility and Sterility 79 : 562-566
16. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L . 1999. Metformininduced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome . Metabolism: Clinical and Experimental 48 : 511-519
17. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I et al. 2008 Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome . European Journal of Endocrinology 159: 399-406
18. Jude EB, Dang C, Boulton AJ . 2010 . effect of L-arginine on the microcirculation in the neuropathic diabetic foot in Type 2 diabetes mellitus: A double-blind, placebo-controlled study . Diabetic Medicine 27: 113-116
19. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM . 2002 . Altered vascular function in young women with polycystic ovary syndrome . Journal of Clinical Endocrinology and etabolism 87 : 742-746
20. Ketel IJ, Stehouwer CD, Sern é EH, Korsen TJ, Hompes PG, Smulders YM et al . 2008 . Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance . Journal of Clinical Endocrinology and Metabolism 93 : 3365-3372
21. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A et al. 2005. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome . Journal of Clinical Endocrinology and Metabolism 90: 5088-5095
22. Legro RS, Finegood D, Dunaif A . 1998 . A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome . Journal of Clinical Endocrinology and Metabolism 83 : 2694-2698
23. Lord JM, Flight IH, Norman RJ . 2003. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis . British Medical Journal 327 : 951-953
24. Lowenstein L, Damti A, Pillar G, Shott S, Blumenfeld Z . 2007. Evaluation of endothelial function in women with polycystic ovary syndrome European Journal of Obstetrics, Gynecology, and Reproductive Biology 134 : 208-212
25. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T et al . 2004 . Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome . Journal of Clinical Endocrinology and Metabolism 89: 4588-4593
26. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R et al. 1989 . Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and aft er weight loss . Journal of Clinical Endocrinology and Metabolism 68: 173-179
27. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC . 1999. The insulinrelated ovarian regulatory system in health and disease . Endocrine Reviews 20 : 535-582
28. Ridker PM . 2003 . Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369
29. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . 2004 . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome . Fertility and Sterility 81 : 19-25
30. Rouzi AA, Ardawi MS . 2006 . A randomized controlled trial of the effi cacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertility and Sterility 85: 428-435
31. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P et al. 2005. Direct thiazolidinedione action in the human ovary: Insulin-independent and insulin-sensitizing eff ects on steroidogenesis and insulin-like growth factor binding protein-1 production . Journal of Clinical Endocrinology and Metabolism 90: 6099-6105
32. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD .1996 . Obesity/insulin resistance is associated with endothelial dysfunction . Implications for the syndrome of insulin resistance. Journal of Clinical Investigation 97(11): 2601-2610
33. Tarkun I, Arslan BC, Cant ürk Z, T üremen E, Sahin T, Duman C . 2004.Endothelial dysfunction in young women with polycystic ovary syndrome: Relationship with insulin resistance and low-grade chronic infl ammation. Journal of Clinical Endocrinology and Metabolism 89: 5592-5596
34. Tarkun I, Cetinarslan B, T ü remen E, Sahin T, Cant ü rk Z, Komsuoglu B . 2005 . effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. European Journal of Endocrinology 153: 115-121
35. Wander K, Brindle E, O ' Connor KA . 2008. C-reactive protein across the menstrual cycle. American Journal of Physical Anthropology 136: 138-146
36. Yilmaz M, Karako ç A, T ö r üner FB, Cakir N, Tiras B, Ayvaz G et al. 2005 The eff ects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome . Gynecological Endocrinology 21 : 154-160
37. Yki-Järvinen H . 2004. Thiazolidinediones . New England Journal of Medicine 351: 1106-1118
38. Zheng Z, Li M, Lin Y, Ma Y . 2002 . [Eff ect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome] . Zhonghua Fu Chan Ke Za Zhi 37: 271-273
39. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J et al . 2010 . Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study . Lancet 376: 103-111